Gross proceeds totaled about $35 million, with net proceeds of $32.8 million to fund SFP clinical trials and for other general corporate purposes...The remainder of the net proceeds will be used for continued commercialization of its products, development of its product candidates and for general corporate purposes

Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 million...Funds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs

Net proceeds of about $13.2 million will be used primarily to support the commercial introduction of Surfaxin, its surfactant product approved last year for respiratory distress syndrome in premature infants, and the Afectair aerosol-conducting airway connector for infants, as well as for general corporate purposes...Net proceeds are expected to total about $16.1 million and will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for

The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Net proceeds will be used primarily for working capital, R&D and general corporate purposes

The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Idera plans to use net proceeds for a Phase II trial with IMO-8400 in patients with psoriasis, and for working capital and general corporate purposes

Net proceeds of about $86.4 million will be used in part – $19.6 million – to repay in full the company's borrowings under and terminate its credit facility...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.

Net proceeds will be used to support R&D activities, working capital and general corporate purposes...The funding allowed ReXceptor to enter a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial of an AD program licensed from Case Western's Technology Transfer Office and based on discoveries that bexarotene, a medication sold at Targretin for cutaneous T-cell lymphomas, reversed AD symptoms in mice within 72 hours of a

12, for net proceeds of approximately $9.9 million...Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes

Most of the net proceeds from the proposed IPO would go toward advancing those two compounds, though Receptos said it might also in-license additional programs...Net proceeds will be used for general corporate purposes

Net proceeds will be used to cover costs related to the new drug application for CompleoTRT, making a milestone payment for CompleoTRT, manufacturing scale-up for CompleoTRT and Tefina clinical trials

Net proceeds totaled $12 million and will be used to fund R&D and clinical trials, acquisition of intellectual property and other purposes...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes

Net proceeds of about $12 million will be used to support R&D, acquisition of intellectual property related to complementary drug therapies, clinical trials and other expenses

Cerus anticipates using the net proceeds for clinical development and other R&D activities related to the Intercept Blood System, preparatory activities for the potential commercialization of the system in the U.S...The net proceeds to Hyperion are about $64.5 million

Oculus plans to use net proceeds for general corporate purposes, including repaying a portion of certain long-term debt...at the same unit price.

The net proceeds are intended to fund preclinical research and development efforts in the areas of infectious diseases, including respiratory syncytial virus, malaria and anthrax, and to support Phase I trials for those programs...Net proceeds are expected to be about $79.2 million

Funds will be used to support clinical trials and for working capital and general corporate purposes. (See BioWorld Today, Feb. 7, 2013...Net proceeds are expected to total about $8.13 million and will support the firm's work on compounded drug formulations

The net proceeds will be used for working capital and general corporate purposes, including the continuation of the Abili-T clinical study, Opexa's ongoing Phase IIb trial of Tcelna in secondary progressive multiple sclerosis patients

The company reports having about $19 million in cash after the financing, enough for the first clinical trials for its broad-spectrum anti-influenza drug candidate, FluCide...Aggregate net proceeds to the company were about $49 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by NewLink